Sung Nam

in an environment where there might be significant CapEx spending going towards U.S., expanding U.S. manufacturing reshoring, et cetera. by potential pressure on the early stage

I was wondering about academic market outside the U.S., whether Spatial could be growing faster? And then also the recent launch of spatial protein proximity detection

how quickly do you do you expect the customers to adopt the multi omni capabilities whether that would require further market development?

would you be able to comment on kind of how Biotech stacks up against competitors on that front? How game changing is this capability

Was wondering if there might be any updates in terms of any of the partnership opportunities, especially with the Exosome Diagnostics' technology

could you maybe elaborate further in terms of which of the product or business segments where you might have seen the strongest growth in the quarter?

Was curious about tariffs, specifically with India currently, just assuming that's not affecting your generics business

Just curious about your drug discovery business out -- for your pharma end market, recognizing that's a very small part of your business

could you remind us kind of what is the latest number for that in terms of your exposure? And then also curious kind of what you're seeing on the ground currently